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LETTER TO THE EDITOR
Reply to the letter from Blay et al.
Pretreatment serum CRP and response to interleukin 2
Sir- We read with interest the letter from Blay et al.
confirming our initial findings in patients with metastatic
colorectal cancer that pretreatment measurement of serum
C-reactive protein (CRP) levels could predict which patients
with metastatic renal cancer would respond to rIL-2-based
therapy. Our preliminary data have also indicated that there
are differences in other acute-phase proteins (albumin, trans-
ferrin, retinol-binding protein and transferrin) between
patients who do or do not respond to rIL-2 treatments.
Furthermore, we have also found that these measurements
not only predict tumour response (in terms of reduction in
tumour volume) but also predict the survival of these
patients following treatment.
The reasons for this are unclear, but Blay et al. have
suggested that CRP, which has well-documented immunosup-
pressive effects, may be inhibiting some of the biological
mechanisms responsible for the anti-neoplastic effect of rIL-2
in vivo. However, CRP has also been documented to activate
complement, stimulate macrophage phagocytosis and
enhance lymphocyte proliferation and cytotoxicity (Vetter et
al., 1983) and therefore the situation in vivo may be more
complex. Furthermore, in our study patients who responded
to rIL-2 treatment demonstrated rising levels of CRP during
the rIL-2 infusion, whereas those who failed to respond had
no change in the levels of CRP during the infusion.
However, we agree that these findings have important
implications in the selection of patients for rIL-2 therapy and
that evaluation of the functions of CRP may allow further
understanding of the complex relationship between acute-
phase reactants and the cytokine system.
Yours etc.
Steven D. Heys',
John Broom2,
Oleg Eremin',
'Department of Surgery,
2Department of Clinical Biochemistry,
University of Aberdeen,
Polworth Building, Foresterhill,
Aberdeen, AB9 2ZD, UK.
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